Abstract
IntroductionA new therapeutic option for metastatic castration–resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in 177Lu-PSMA-617 radioligand therapy.MethodsOn the basis of PSMA-targeted 68Ga-PSMA-11 PET/CT, 32 consecutive mCRPC patients were selected for 177Lu-PSMA-617 therapy (6 GBq/cycle, 2 to 6 cycles, 6–10 weeks apart) and followed until death. Post-therapy whole-body (WB) dosimetry and 68Ga-PSMA-11 PET/CT data were compared and related to progression free and overall survival.Results177Lu-PSMA-617 dosimetry after the first cycle indicated high tumor doses for skeletal (4.01 ± 2.64; range 1.10–13.00 Gy/GBq), lymph node (3.12 ± 2.07; range 0.70–8.70 Gy/GBq), and liver (2.97 ± 1.38; range 0.76–5.00 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 24 GBq. Any PSA decrease after the first cycle was found in 23/32 (72%), after the second cycle in 22/32 (69%), after the third cycle in 16/28 (57%), and after the fourth cycle in 8/18 (44%) patients. Post-therapy 24 h WB scintigraphy showed decreased tumor-to-background ratios in 24/32 (75%) after the first therapy cycle, after the second cycle in 17/29 (59%), and after the third cycle in 13/21 (62%) patients. The median PFS was 7 months and the median OS 12 months. In the group of PSA responders (n = 22) the median OS was 17 months versus 11 months in the group of non-responders (n = 10), p < 0.05. Decreasing SUVmax values were found for parotid (15.93 ± 6.23 versus 12.33 ± 4.07) and submandibular glands (17.65 ± 7.34 versus 13.12 ± 4.62) following treatment, along with transient (n = 6) or permanent (n = 2) xerostomia in 8/32 (25%) patients. In 3/32 patients, nephrotoxicity changed from Grade 2 to 3, whereas neither Grade 4 nephrotoxicity nor hematotoxicity was found. In most patients a good agreement was observed for the visual interpretation of the tracer accumulation between 24 h WB and PET/CT scans. However, no significance could be calculated for baseline-absorbed tumor doses and SUVmax values of tumor lesions. 5/32 (16%) patients showed a mixed response pattern, which resulted in disease progression over time.ConclusionSerial PSA measurements and post-therapy 24 h WB scintigraphy seems to allow a sufficiently accurate follow-up of 177Lu-PSMA-617-treated mCRPC patients whereas 68Ga-PSMA-11 PET/CT should be performed for patient selection and final response assessment.
Highlights
A new therapeutic option for metastatic castration–resistant prostate cancer of heavily pre-treated patients lies in 177Lu-PSMA-617 radioligand therapy
All patients were informed about the experimental nature of the 177Lu-PSMA-617 therapy and no systematic patient selection was performed
The following consecutive 22 patients were prospectively assigned to undergo 177Lu-PSMA-617 therapy with four cycles applied 6 weeks apart as dosimetry had shown that higher doses are safe [11]. 177Lu-PSMA-617 was offered as surrogate therapy to patients who were refractory to chemotherapy, monoclonal antibody therapy, and/or hormonal therapy
Summary
A new therapeutic option for metastatic castration–resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in 177Lu-PSMA-617 radioligand therapy. In accordance with the theragnostic concept, 68Ga-PSMA-11 PET/CT can be used to assess response to therapy with 177Lu-/225Ac-PSMA-617 in patients with metastatic castration–resistant PC (mCRPC). In line with the theragnostic concept [6], 68Ga-labelled PSMA ligands are increasingly used to detect lesions in patients with mCRPC, prior to PSMA-directed radioligand therapy (PRLT), and as diagnostic response tool in the follow-up of PRLT-treated patients [1]. Progression free survival (PFS) and overall survival (OS) was correlated to each one of the scores, and different aspects of response assessment are discussed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
